PANCREATIC CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Pancreatic Cancer News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.

March 18, 2019

Lynparza Delays Progression of BRCA-mutated Metastatic Pancreatic Cancer

By Anonymous User anonymous_user_10987

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the worst survival rate of the most common cancers and less than seven percent of patients survive more than […]

View full entry

Tags: News Tips and Features, News Tips and Features Other, Pancreatic Cancer


February 28, 2019

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

By Anonymous User anonymous_user_10987

Results from the trial showed a significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) for the treatment of BRCA-mutated pancreatic cancer. POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose […]

View full entry

Tags: News Tips and Features, News Tips and Features Other, Pancreatic Cancer


October 19, 2018

Laurie MacCaskill Partners with CancerConnect

By Anonymous User anonymous_user_10987

KETCHUM – LOS ANGELES: Laurie MacCaskill, a 12-year survivor of pancreatic cancer and former chair of the Pancreatic Cancer Action Network has announced a newly established partnership with Cancer Connect to support pancreatic cancer patients with information, support and inspiration. Cancer Connect, a national organization provides support and information to more than 1 million patients […]

View full entry

Tags: News Tips and Features, News Tips and Features Other, Pancreatic Cancer


June 19, 2018

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

By Anonymous User anonymous_user_10987

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of […]

View full entry

Tags: Chemotherapy, gemzar, mFOLFIRINOX, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, treatment


First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By Anonymous User anonymous_user_10987

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


Pamrevlumab Awarded "Fast Track" Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News Tips and Features, News Tips and Features Other, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment


Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Precision Cancer Medicine, treatment


A Global Phase 3 Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Metastatic Pancreatic Cancer

August 15, 2017

A Global Phase 3 Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Metastatic Pancreatic Cancer

By cancerconnect cancerconnect

A new clinical study will investigate napabucasin – an orally administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3 – in combination with standard of care (nab-paclitaxel plus gemcitabine) in patients with metastatic pancreatic cancer. Patients in the trial will be randomized in a 1:1 ratio to receive either two daily doses […]

View full entry

Tags: Cancer Stemness Inhibitor Napabucasin, clinical trial, News Tips and Features, News Tips and Features Other, Pancreatic Cancer


View more articles like this
More news and in-depth Pancreatic Cancer information

CONDITIONS OF THE GI TRACT